Francesco Rodeghiero

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype

David Lillicrap, Barbara Zieger, R Lassila, Alessandro Casini et autres

In a previous paper, a comprehensive clinicopathologic approach to mild and moderate bleeding disorders (MBD) was proposed by an international working group (IWG) as a part of a project promoted by the European Hematology Association (EHA) on the development of guidelines on …

us (code pays fourni par la source)

Long-Term Safety and Efficacy of Efgartigimod in Adults with Primary Immune Thrombocytopenia: Interim Results of the ADVANCE IV+ Phase 3 Trial

Monica Carpenedo, Catherine M. Broome, Blanca Sánchez‐González, Vickie McDonald et autres

it, us (code pays fourni par la source)

Introduction to the Review Series. A century after Erik von Willebrand

P.M. Mannucci, Francesco Rodeghiero

it (code pays fourni par la source)

Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)

Monica Carpenedo, Catherine M. Broome, Blanca Sánchez González, Vickie McDonald et autres

Abstract Introduction Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder resulting in thrombocytopenia, bleeding, constitutional symptoms, and impaired health-related quality of life (HRQoL). Although various ITP treatment options are available, many patients do not have a sustained clinical response and require …

it, us, es, gb, jp, be, fr (code pays fourni par la source)

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

Guillaume Moulis, Frederick Chen, Giuseppe Carli, Waleed Ghanima et autres

Not available.

fr, gb, it, no, de, us, ch, es (code pays fourni par la source)

Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype

Francesco Rodeghiero, Lisanna Ghiotto, Luca Pontalto, Alessandro Casini et autres

In a previous paper, a comprehensive clinicopathologic approach to mild and moderate bleeding disorders (MBD) was proposed by an international working group (IWG) as a part of a project promoted by the European Hematology Association (EHA) on the development of guidelines on …

it, ch, gb, se, hu, nl, us, fi, ca, cl, at, in, pl, de (code pays fourni par la source)

Bleeding Risk of Immune Thrombocytopenia and Its Management

Francesco Rodeghiero

it (code pays fourni par la source)

Thrombopoietin Receptor Agonists and Agents Under Development to Increase Platelet Count in Immune Thrombocytopenia

Francesco Rodeghiero

it (code pays fourni par la source)

The epidemiology of von Willebrand disease

Giancarlo Castaman, Francesco Rodeghiero

Epidemiological studies have shown that the prevalence of Von Willebrand disease (VWD) may be as high as 1%. This figure has been obtained by using conservative clinical and laboratory criteria. However, many of the subjects identified by this means will experience only …

it (code pays fourni par la source)

Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial

Maria Gabriella Mazzucconi, Francesco Rodeghiero, Giuseppe Avvisati, Valerio De Stefano et autres

ABSTRACT: A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly …

it, au (code pays fourni par la source)

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo et autres

Background In primary immune thrombocytopenia (ITP), immunoglobulin G (IgG) anti-platelet autoantibodies contribute to platelet clearance and impair platelet production. IgG homeostasis is regulated by the neonatal Fc receptor (FcRn), which binds to IgG in a pH-dependent manner and recycles bound IgG. Efgartigimod …

us, gb, jp, it, be, fr (code pays fourni par la source)

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Catherine M. Broome, David J. Kuter, Hanny Al‐Samkari, James B. Bussel et autres

us, gb, jp, it, be, fr (code pays fourni par la source)